JP2024125140A - アズブジンと化学療法剤とを含む抗腫瘍医薬組成物 - Google Patents

アズブジンと化学療法剤とを含む抗腫瘍医薬組成物 Download PDF

Info

Publication number
JP2024125140A
JP2024125140A JP2023083815A JP2023083815A JP2024125140A JP 2024125140 A JP2024125140 A JP 2024125140A JP 2023083815 A JP2023083815 A JP 2023083815A JP 2023083815 A JP2023083815 A JP 2023083815A JP 2024125140 A JP2024125140 A JP 2024125140A
Authority
JP
Japan
Prior art keywords
tumor
cancer
pharmaceutical composition
chemotherapeutic agent
azuvidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023083815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024125140A5 (https=
Inventor
パン・リー
Pan Li
リミン・ジア
Limin Jia
ジヨン・シン
Zhiyong Qin
ザオヤン・ワン
Zhaoyang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Genuine Biotech Co Ltd
Original Assignee
Henan Genuine Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Genuine Biotech Co Ltd filed Critical Henan Genuine Biotech Co Ltd
Publication of JP2024125140A publication Critical patent/JP2024125140A/ja
Publication of JP2024125140A5 publication Critical patent/JP2024125140A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023083815A 2023-03-03 2023-05-22 アズブジンと化学療法剤とを含む抗腫瘍医薬組成物 Pending JP2024125140A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310201602.2 2023-03-03
CN202310201602.2A CN116407640B (zh) 2023-03-03 2023-03-03 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Publications (2)

Publication Number Publication Date
JP2024125140A true JP2024125140A (ja) 2024-09-13
JP2024125140A5 JP2024125140A5 (https=) 2026-04-20

Family

ID=86497784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023083815A Pending JP2024125140A (ja) 2023-03-03 2023-05-22 アズブジンと化学療法剤とを含む抗腫瘍医薬組成物

Country Status (7)

Country Link
US (1) US12268702B2 (https=)
EP (1) EP4424316B1 (https=)
JP (1) JP2024125140A (https=)
KR (1) KR20250167640A (https=)
CN (1) CN116407640B (https=)
TW (1) TW202435896A (https=)
WO (1) WO2024183645A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物
CN116196325A (zh) * 2023-03-10 2023-06-02 河南真实生物科技有限公司 包含阿兹夫定的免疫调节剂组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2201296T3 (es) * 1996-04-26 2004-03-16 Genaera Corporation Escualmina en combinacion con otros farmacos anticancerigenos para el tratamiento de tumores.
CN102000103B (zh) * 2009-12-21 2011-12-21 郑州大学 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用
CA2873112A1 (en) * 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
JP6878417B2 (ja) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド 剤形およびそれらの使用
EP3508205B1 (en) * 2016-08-31 2022-05-18 FUJIFILM Corporation Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
WO2020001475A1 (en) * 2018-06-29 2020-01-02 Shanghai Changchengyiyaokeji Company Limited Phosphorus-containing prodrugs of gemcitabine
WO2020142629A1 (en) * 2019-01-02 2020-07-09 The General Hospital Corporation Reverse transcriptase blocking agents and methods of using the same
WO2021209740A1 (en) * 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
US20230218644A1 (en) * 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
TW202228724A (zh) * 2020-09-23 2022-08-01 美商昂克萊亞製藥公司 以反轉錄酶抑制劑治療癌症之方法
CN116407640B (zh) * 2023-03-03 2025-10-31 河南真实生物科技有限公司 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物

Also Published As

Publication number Publication date
CN116407640B (zh) 2025-10-31
EP4424316A1 (en) 2024-09-04
US12268702B2 (en) 2025-04-08
CN116407640A (zh) 2023-07-11
US20240293438A1 (en) 2024-09-05
TW202435896A (zh) 2024-09-16
EP4424316C0 (en) 2025-07-02
EP4424316B1 (en) 2025-07-02
WO2024183645A1 (zh) 2024-09-12
KR20250167640A (ko) 2025-12-01

Similar Documents

Publication Publication Date Title
US9358233B2 (en) Method for treating acute myeloid leukemia
KR20140079831A (ko) 췌장암 및／또는 담도암 치료약
EP4005591A1 (en) Anti-neoplastic combined pharmaceutical composition and application thereof
JP2024125140A (ja) アズブジンと化学療法剤とを含む抗腫瘍医薬組成物
WO2018015526A1 (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
KR20250166964A (ko) 아즈부딘을 포함한 항종양 약학적 조성물
US20170173023A1 (en) Combination therapy with volasertib
EP2928456B1 (en) Treatment of hematological cancer refractory to an anti-cancer agent
CN109528731B (zh) 具有协同作用治疗多发性骨髓瘤的药物组合物及其应用
TWI454280B (zh) Pharmaceutical composition or combination
JP6895688B2 (ja) 血液がんの新規治療法及び新規治療剤
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
EP3487499A1 (en) Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
CN108503676B (zh) 用于癌症治疗的果糖类似物及其组合物
EP2826482A1 (en) Novel antitumor agent comprising combination of three agents
US11179349B2 (en) Use of tumor gene methylation regulator and anti-tumor drugs
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
US20060058260A1 (en) Combination therapy with gemcitabine and zd6126

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260410

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20260410